{"id":"W4381715763","doi":"10.1001/jamanetworkopen.2023.19607","title":"Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma","year":2023,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Pembrolizumab; Internal medicine; Oncology; Melanoma; Clinical endpoint; Clinical trial; Censoring (clinical trials); Immunotherapy; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006063218,0.0004721254,0.0009446662,0.0001323819,0.0003270199,0.0002581328,0.0008306456,0.0002780016,0.000808557],"category_scores_gemma":[0.00009982411,0.0004044405,0.0004575026,0.0008131267,0.0001247378,0.0003971297,0.0004225048,0.000196486,0.0002216057],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005345415,"about_ca_system_score_gemma":0.0003547397,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000706892,"about_ca_topic_score_gemma":0.001150202,"domain_scores_codex":[0.9970022,0.0001415272,0.0006044419,0.0008043038,0.0003995225,0.001048017],"domain_scores_gemma":[0.9976113,0.0003537807,0.0002031479,0.001443175,0.0001478518,0.0002407233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.4242189,0.0005870636,0.042357,0.0002657827,0.002244561,0.000476981,0.0009601291,0.0001984554,0.0007501069,0.0003677751,0.2402307,0.2873425],"study_design_scores_gemma":[0.09791402,0.007408902,0.2572754,0.0005826619,0.0004549462,0.0001098626,0.0003656243,0.001858586,0.0004879326,0.0009311324,0.6317263,0.0008846381],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9636996,0.002632214,0.0001268241,0.011028,0.002314229,0.005358995,0.0003137859,0.0004534286,0.01407292],"genre_scores_gemma":[0.9336751,0.001781939,0.001982163,0.001774951,0.002346314,0.002458256,0.0006305504,0.0002108741,0.0551399],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3914956,"threshold_uncertainty_score":0.9998407,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02428160445229956,"score_gpt":0.3016705749623989,"score_spread":0.2773889705100994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}